NCT05763550View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Herpetic Neuralgia

PHASE2CompletedINTERVENTIONAL
Enrollment

331

Participants

Timeline

Start Date

February 27, 2023

Primary Completion Date

June 22, 2023

Study Completion Date

August 7, 2023

Conditions
Herpetic Neuralgia
Interventions
DRUG

HSK16149 20mg BID

HSK16149 20mg, orally twice a day, treatment period; 4-weeks fixed dose.

DRUG

HSK16149 40mg BID

HSK16149 40mg, orally twice a day, treatment period; 4-weeks fixed dose.

DRUG

Pregabalin 150mg

pregabalin, orally twice a day, treatment period; 150 mg (75 mg twice daily) for 1 week；300 mg (150 mg twice daily) daily for 3 week

Trial Locations (1)

430000

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY